Published June 2014 | Version v1
Journal article

The Ca2+-activated Cl channel, ANO1 (TMEM16A), is a double-edged sword in cell proliferation and tumorigenesis

  • 1. State Key Physiological Discipline, Qingdao University, Qingdao, 266555 (China)
  • 2. Medical Research Center, Affiliated Hospital, Qingdao University, Qingdao, 266555 (China)
  • 3. Department of Neurosurgery, Affiliated Hospital, Qingdao University, Qingdao, 266555 (China)
  • 4. Department of Cell Biology, School of Medicine, Emory University, 30322,Atlanta (United States)

Description

Since anoctamin 1 ANO1 (TMEM16A) was found to be a molecular component of Ca2+-activated Cl channels, its role in tumorigenesis has gained attention at a fast pace. ANO1 overexpression frequently occurs in the cancer tissues along with 11q13 chromosome amplification. Poor prognosis of many types of cancers has been closely correlated with ANO1 gene amplification and protein overexpression. ANO1 is now considered an excellent biomarker for certain cancers. Recent research suggests that it is the channel function of ANO1 that is involved in the tumorigenesis. However, how the overexpression of the functional ANO1 causes malignant transformation of tissues via signaling pathways, for example, MAPK remains to be investigated. Clarification of the reasons in future will avail to make ANO1 as a target for cancer treatment

Availability note (English)

Available from http://dx.doi.org/10.1002/cam4.232; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4101736

Additional details

Publishing Information

Journal Title
Cancer medicine
Journal Volume
3
Journal Issue
3
Journal Page Range
p. 453-461
ISSN
2045-7634

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
46049549
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
CELL PROLIFERATION; NEOPLASMS; PROTEINS
Descriptors DEC
DISEASES; ORGANIC COMPOUNDS

Optional Information

Copyright
Copyright (c) 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Notes
PMCID: PMC4101736; PMID: 24639373; OAI: oai:pubmedcentral.nih.gov:4101736